×
About 7,345 results

ALLMedicine™ Malignant Melanoma Center

Research & Reviews  2,559 results

Neoadjuvant therapy for melanoma: new and evolving concepts.
https://www.ncbi.nlm.nih.gov/pubmed/35060962
Clinical Advances in Hematology & Oncology : H&O; Erstad DJ, Witt RG et. al.

Jan 22nd, 2022 - Effective systemic therapies, including targeted BRAF/MEK inhibition and immune checkpoint blockade, have significantly changed the treatment landscape for malignant melanoma. Specifically, there have been promising clinical trial findings associa...

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhi...
https://doi.org/10.1007/s13311-022-01184-0
Neurotherapeutics : the Journal of the American Society F... Duong SL, Prüss H

Jan 20th, 2022 - The introduction of immune checkpoint inhibitors (ICIs) in oncologic therapies has led to a paradigm shift in cancer treatment. ICIs have increased the overall survival in patients with malignant melanoma, small-cell lung cancer, and many other tu...

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
https://clinicaltrials.gov/ct2/show/NCT03377491

Jan 19th, 2022 - PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro and in vivo pancreatic adenocarcinoma pre-clinical models both as a single modality treatment and in com...

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
https://clinicaltrials.gov/ct2/show/NCT04315246

Jan 19th, 2022 - Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will receive a dosimetry dose followed by maximum of five 5-week cycles of treatment doses of intracerebroventricular 177Lu-DTPA-omburtamab. Part 2 is a cohort-...

see more →

Guidelines  2 results

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cance...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882649
International Journal of Clinical Oncology; Saito T, Tabata T et. al.

Nov 22nd, 2017 - Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines...

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment an...
https://doi.org/10.1093/annonc/mdn100
Annals of Oncology : Official Journal of the European Soc... Dummer R, Hauschild A et. al.

May 9th, 2008 - Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Dummer R,Hauschild A,Jost L, ,|diagnosis,epidemiology,pathology,therapy,diagnosis,epidemiology,pathology,therapy,

see more →

Drugs  9 results see all →

Clinicaltrials.gov  124 results

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
https://clinicaltrials.gov/ct2/show/NCT03377491

Jan 19th, 2022 - PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro and in vivo pancreatic adenocarcinoma pre-clinical models both as a single modality treatment and in com...

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
https://clinicaltrials.gov/ct2/show/NCT04315246

Jan 19th, 2022 - Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will receive a dosimetry dose followed by maximum of five 5-week cycles of treatment doses of intracerebroventricular 177Lu-DTPA-omburtamab. Part 2 is a cohort-...

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
https://clinicaltrials.gov/ct2/show/NCT02020707

Jan 11th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximally tolerated dose (MTD-malignant melanoma [MM]) of Abraxane (nab-paclitaxel)/bevacizumab-complex (AB-complex) among patients with metastatic malignant melanoma. II. To determine the maximally tolerate...

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
https://clinicaltrials.gov/ct2/show/NCT01740557

Dec 10th, 2021 - PRIMARY OBJECTIVES: I. To assess the feasibility and safety of CXCR2 and NGFR transduced tumor-infiltrating lymphocytes (TIL) for treating metastatic malignant melanoma. SECONDARY OBJECTIVES: I. Determine whether CXCR2 transduction enhances the ab...

SkIN hydrAtion Evaluation With TeRAhertz Scanning
https://clinicaltrials.gov/ct2/show/NCT05121207

Nov 16th, 2021 - The SINATRA study is pilot study with a primary aim to explore the feasibility of the trial methodology. In addition, secondary objectives of the study will investigate if THz light is able to detect subtle differences in skin hydration and their ...

see more →

News  244 results

Pioneering Test Predicts Return of Malignant Melanoma
http://www.medscape.com/viewarticle/966605

Jan 14th, 2022 - Scientists at Newcastle University have identified the mechanism for skin cancer growth. Their research, published in the British Journal of Dermatology , describes how early-stage melanomas at risk of spreading secrete a growth factor, called TGF...

Pioneering Test Predicts Return of Malignant Melanoma
https://www.medscape.com/viewarticle/966605

Jan 14th, 2022 - Scientists at Newcastle University have identified the mechanism for skin cancer growth. Their research, published in the British Journal of Dermatology , describes how early-stage melanomas at risk of spreading secrete a growth factor, called TGF...

Some diuretics tied to increased skin cancer risk
https://www.mdedge.com/hematology-oncology/article/248047/nonmelanoma-skin-cancer/some-diuretics-tied-increased-skin-cancer
Pam Harrison

Oct 28th, 2021 - Researchers writing in the British Journal of Dermatology confirm the long-term use of hydrochlorothiazide is associated with a dose-dependent, twofold increased risk of squamous cell carcinoma, compared with calcium channel blocker use. The findi.

FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma
https://www.onclive.com/view/fda-grants-fast-track-status-to-cancer-vaccine-uv1-for-advanced-malignant-melanoma

Oct 25th, 2021 - The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab (Keytruda) or to ...

Fecal Microbiota Transplants May Improve Resistance to Melanoma Immunotherapy
https://www.medscape.com/viewarticle/961360

Oct 21st, 2021 - In the fall of 2020, Hassane M. Zarour, MD, and colleagues began to pore over raw data from their phase 1 clinical trial designed to determine if fecal microbiota transplantation (FMT) could reprogram the gut microbiome in advanced melanoma patien...

see more →